Arabica coffee oil extract enhances neuronal resilience under hypoxic stress through HIF-1α and EGFR signaling modulation

Submitted by Anonymous on

AbstractBackground Hypoxia is a critical factor contributing to neuronal injury, primarily through dysregulation of hypoxia-inducible factor-1 alpha (HIF-1α). This study aimed to investigate the neuroprotective effects of Arabica coffee oil extract under hypoxic conditions in neuronal cells and to elucidate...

Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoing EGFR-targeted therapy and literature review

Submitted by Anonymous on

Abstract Malignant Adenomyoepithelioma (MAME) is a very rare tumor derived from the mixed proliferation of glandular epithelium and muscular epithelium. It has a wide spectrum of histomorphology, a high risk of local recurrence and distant metastasis, and there are few...

Propionate metabolism is dysregulated in non-small cell lung cancer patients and EGFR-mutant drug-tolerant persister cells

Submitted by Anonymous on

Recent studies show that genetic sequencing can not fully explain drug resistance in non-small cell lung cancer (NSCLC), suggesting undiscovered non-genetic mechanisms that can enable cancer cell survival. Propionate metabolism is the pathway by which odd-chain fatty acids, branched chain...

Renal Functional Reserve and Its Association with eGFR Trajectories and Blood Pressure Patterns in Hypertensives with Preserved Renal Function

Submitted by Anonymous on

AbstractIntroduction Renal Functional Reserve (RFR) is a promising marker for detecting early nephron loss and functional renal mass. Aim We evaluated the relationship between RFR and changes in eGFR over time in hypertensive (HT) and normotensive (NT) individuals. Methods In...

Repression of EGFR by new biguanide 4C potentiated ovarian cancer to PARP inhibitors through down-regulation of BRCA2 and Rad51

Submitted by Anonymous on

EGFR, one of the most successful therapeutic targets, has recently been found to exert a novel function for regulating homologous recombination (HR). Activation of HR is the critical event of treatment failure of PARPi in BRCA1/2 wild-type ovarian cancer (OC)....

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal modelsSuperior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with favorable...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

Unique structural features of firmonertinib enhance binding and activity against EGFR mutant proteins including ex20ins mutant proteins in cell lines and NSCLC animal models Superior anti-tumor activity of ARR-002 in ovarian cancer models compared to single-target or bivalent approaches with...

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual...

Black Diamond Therapeutics (BDTX) Advances Silevertinib Trials in EGFR-Related Cancers

Submitted by Anonymous on

Key Takeaways: Black Diamond Therapeutics BDTX is advancing its silevertinib treatment for EGFR mutations in NSCLC and GBM. The company plans to present updated Phase 2 trial results in 2026, focusing on duration of response and progression-free survival. Black Diamond...

Subscribe to Newsfeed